Review reports higher circulating PCSK9 after lipid-lowering treatment
Pooled trials found an increase in this blood protein, but the abstract does not report cardiovascular outcomes or show that monitoring it improves care.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported higher circulating PCSK9 following conventional lipid-lowering treatment. That is a laboratory finding, and the abstract does not say whether participants experienced more or fewer cardiovascular events. Although the authors recommend monitoring this protein, the reported results do not establish that monitoring would improve patient outcomes or guide a beneficial treatment change.
The methods name standardized mean differences, while the results report a weighted mean difference. The abstract also leaves the pooled comparator unclear, limiting interpretation of the estimate in this abstract-based summary.
What evidence was combined
The review combined randomized trials in adults receiving a lipid-lowering drug alone or in combination. Eligible trials recorded PCSK9 before and after treatment, and the review considered lipid profiles alongside the protein measurements.
What varied across trials
The authors reported differences in results by treatment intensity, drug class, underlying disease, and study location. The abstract does not supply those subgroup estimates, so it cannot identify a particular treatment as producing the largest protein change.
The original publication
Impact of conventional lipid-lowering therapy on circulating levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis of randomised controlled trials.
Meng L, Huang T, Guo S et al.
Diabetes Obes Metab · 2026
- PubMed ID
- 41656962
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.